Charts

Gainers Adial Pharmaceuticals (NASDAQ:ADIL) stock increased by 90.4% to $0.8 during Monday's after-market session. Trading volume for ...

Gainers Sera Prognostics, Inc. (NASDAQ: SERA) shares surged 63.4% to $2.11 after the company announced top-line data from the ...

Gainers TransCode Therapeutics (NASDAQ:RNAZ) shares rose 95.7% to $0.92 during Wednesday's pre-market session. The company's market cap ...

Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 69.1% to $0.7948 in pre-market trading after the company requested ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off another day of trading with a breakdown of the biggest pre-market stock movers for trader need to kno about Wednesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

Gainers Humanigen (NASDAQ:HGEN) shares moved upwards by 31.9% to $0.24 during Tuesday's after-market session. This security traded at a ...

Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares rose 52.5% to $0.7050 in pre-market trading after jumping over 72% on ...

Gainers Tricida, Inc. (NASDAQ: TCDA) rose 37.7% to $0.1898 in pre-market trading after gaining 4% on Wednesday. Huadi ...

Gainers Vyant Bio, Inc. (NASDAQ: VYNT) shares rose 110.4% to $1.62 in pre-market trading after the company said it has engaged ...

Gainers Immuron (NASDAQ:IMRN) stock rose 42.9% to $2.3 during Monday's pre-market session. The market value of their outstanding shares ...

Gainers Immuron (NASDAQ:IMRN) stock increased by 42.2% to $2.29 during Friday's pre-market session. The company's market cap stands at ...

San Diego, CA -- (SBWIRE) -- 12/15/2022 -- An investigation was announced for current long-term investors in shares of Humanigen, Inc. (NASDAQ: HGEN) concerning potential breaches of fiduciary duties by certain directors of Humanigen, Inc.

Gainers PLx Pharma (NASDAQ:PLXP) stock increased by 10.6% to $0.23 during Wednesday's after-market session. The market value of their ...

The FDA hasissueda notice regarding the safety and effectiveness of certain naloxone hydrochloride products for ...

Gainers Abiomed, Inc. (NASDAQ: ABMD) shares surged 49.9% to settle at $377.82 on Tuesday after Johnson & Johnson announced it ...

San Diego, CA -- (SBWIRE) -- 10/26/2022 -- The Shareholders Foundation announced that a deadline is coming up on October 25, 2022 in the lawsuit filed for certain investors of Humanigen, Inc. (NASDAQ:HGEN).

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Humanigen, Inc. (“Humanigen” or “the Company”) (NASDAQ: HGEN) and certain of its officers on behalf of all persons and entities that purchased, or otherwise acquired Humanigen securities between May 28, 2021, and July 12, 2022, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/hgen.

Researchers are working on cures for long COVID. With some success, naltrexone has been used to treat pain, fatigue, and brain fog ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 28, 2021 and July 12, 2022, both dates inclusive (the “Class Period”) of the important October 25, 2022 lead plaintiff deadline.

Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 89.4% to $0.2655 in pre-market trading. Statera Biopharma was recently granted ...

Gainers Vicinity Motor Corp. (NASDAQ: VEV) rose 65.4% to $1.72 in pre-market trading. Vicinity Motor started deliveries of the ...

Gainers Bit Brother Limited (NASDAQ: BTB) rose 229% to $0.3688 after declining around 14% on Monday. Connexa Sports Technologies ...

Gainers Avenue Therapeutics (NASDAQ:ATXI) shares moved upwards by 37.7% to $15.85 during Tuesday's pre-market session. The ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! It's time for a breakdown of the biggest pre-market stock movers traders need to know about for Tuesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

San Diego, CA -- (SBWIRE) -- 09/15/2022 -- An investor, who purchased shares of Humanigen, Inc. (NASDAQ:HGEN), filed a lawsuit over alleged violations of Federal Securities Laws by Humanigen, Inc. in connection with certain allegedly false and misleading statements.

Humanigen accused of overstating the clinical and commercial prospects of treatment for its lead drug candidate.

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Humanigen, Inc. (“Humanigen” or “the Company”) (NASDAQ: HGEN) and certain of its officers on behalf of all persons and entities that purchased, or otherwise acquired Humanigen securities between May 28, 2021, and July 12, 2022, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/hgen.

Humanigen, Inc. (HGEN) Overstated the Clinical and Commercial Prospects of its Lead Drug Candidate

Gainers American Virtual Cloud Technologies, Inc. (NASDAQ: AVCT) climbed 156.3% to close at $0.3750 on Monday. American Virtual ...

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Humanigen, Inc. (“Humanigen” or the “Company”) (NASDAQ: HGEN) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Humanigen securities between May 28, 2021 and July 12, 2022, both dates inclusive (the “Class Period”). Investors have until October 25, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Humanigen, Inc. (HGEN) Overstated the Clinical and Commercial Prospects of its Lead Drug Candidate

Gainers Reviva Pharmaceuticals (NASDAQ:RVPH) stock moved upwards by 72.5% to $2.64 during Monday's regular session. ...

Gainers Advanced Human Imaging Limited (NASDAQ: AHI) shares jumped 53% to $1.04. Advanced Human Imaging announced Sunday it signed ...

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 28, 2021 and July 12, 2022, both dates inclusive (the “Class Period”). If you wish to serve as lead plaintiff, you must move the Court no later than October 25, 2022.

The Schall Law Firm Encourages Investors in Humanigen, Inc. with Losses of $100,000 to Contact the Firm

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Apple (AAPL) stock is in the news as the company may finally be about ready to enter the VR space after years of headset rumors. The post AAPL Stock Alert: Is Apple Making Moves in the Virtual Reality Space? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pinduoduo (PDD) stock is getting a boost on Monday after the Chinese agriculture tech company released results for Q2 2022. The post Why Is Pinduoduo (PDD) Stock Up 18% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Fans of AMC Entertainment (AMC) stock will want to keep an eye on the company come Sept. 3 as it prepares for a special theater event. The post Dear AMC Stock Fans, Mark Your Calendars for Sept. 3 appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Humanigen (HGEN) stock is heading lower on Monday as investors react to a minimum price delisting notice from the Nasdaq Exchange. The post Why Is Humanigen (HGEN) Stock Down 16% Today? appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're breaking down the biggest pre-market stock movers and the news that has them rising and falling for Monday morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Gainers NewAge, Inc. (NASDAQ: NBEV) shares rose 19.7% to $0.2432 in pre-market trading. NewAge recently received Nasdaq notice on ...

The Schall Law Firm Encourages Investors in Humanigen, Inc. with Losses of $100,000 to Contact the Firm

SHORT HILLS, N.J., August 12, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab (LENZ®), a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today reported financial results for the second quarter and six months ended June 30, 2022.

Short Hills, New Jersey--(Newsfile Corp. - July 26, 2022) - Humanigen, Inc. (NASDAQ: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on developing lenzilumab, a first-in class antibody that neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), today announced a strategic realignment of its pipeline and resources to achieve key clinical milestones. The Company plans to accelerate the development of lenzilumab in chronic myelomonocytic leukemia ("CMML"), a

Covid-19 opened up plenty of opportunities for smaller pharma companies to make their mark, by developing either vaccines or treatments. But it’s no easy task getting a product approved, and many have been unable to get their candidates across the finish line. The latest victim in the space appears to be Humanigen (HGEN). Shares took a proper thrashing in Wednesday’s session, after the company disclosed that its experimental antibody Lenzilumab failed to make the grade as a treatment for hospita

SHORT HILLS, N.J., July 13, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen") has been informed of preliminary topline results from the National Institute of Allergy and Infectious Diseases’ (NIAID) ACTIV-5/BET-B trial evaluating lenzilumab plus remdesivir versus placebo plus remdesivir in hospitalized COVID-19 patients. The trial did not achieve statistical significance on the primary endpoint, which was defined as the proportion of patients with baseline CRP

SHORT HILLS, N.J., July 07, 2022--Humanigen Announces Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 patients with Lenzilumab Guided by C-Reactive Protein

SHORT HILLS, N.J., June 30, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, confirms that notice was received today from the National Institute of Allergy and Infectious Diseases (NIAID) that they have completed database lock for the Big Effect Trial of lenzilumab (BET-B) being conducted as part of the National Institute

SHORT HILLS, N.J., June 16, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced it entered into an agreement with PCI Pharma Services (PCI), a leading integrated global contract development manufacturing organization (CDMO), to provide importation, release and commercialization services in the United Kingdom (UK) for lenzilumab. Under the agreement,

The recent 16% drop in Humanigen, Inc.'s ( NASDAQ:HGEN ) stock could come as a blow to insiders who purchased US$154k...

SHORT HILLS, N.J., June 03, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ announced today that representatives will present and participate at multiple investors conferences in June 2022. Details of the conferences are as follows:

SHORT HILLS, N.J., May 24, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ announced that Cameron Durrant, Chairman & CEO, will give a corporate presentation at 11:00am EDT today at the H.C. Wainwright Global Investment Conference taking place in Miami, FL, May 23-26, 2022. In his presentation Dr. Durrant will provide an update on progress towards release of top

Accounting for many stocks losing a huge chunk of their valuations in 2022’s inhospitable stock market, analysts have been busy slashing estimates and price targets this year. However, for H.C. Wainwright analyst Joseph Pantginis, there has been no such change of heart when considering the prospects of biotech company Humanigen (HGEN). Even in the face of FDA rejection and a stock which is down 89% over the past year, Pantginis remains undeterred. The analyst reiterated a Buy rating for HGEN sto

It's nice to see the Humanigen, Inc. ( NASDAQ:HGEN ) share price up 14% in a week. But that doesn't change the fact...

SHORT HILLS, N.J., May 05, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called "cytokine storm" with its lead drug candidate, lenzilumab (LENZ®), today provided a corporate update and reported financial results for the first quarter ended March 31, 2022.

SHORT HILLS, N.J., May 04, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ announced today that management will present and participate at multiple investors conferences in May 2022. Details of the conferences are as follows:

SHORT HILLS, N. J., April 19, 2022--Humanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHS